A scalable manufacturing platform for externally controllable universal CAR T-cell products
Funding Cycle:
2023-2024Name:
Kiyosumi OchiType of Award:
Career Development AwardHome Institution:
The Institute of Medical Science, The University of Tokyo, JapanHost Institution:
Massachusetts General HospitalDescription
Chimeric antigen receptor (CAR) T-cell therapy represents a breakthrough in cancer treatment and has achieved unprecedented success in hematologic malignancies. Recent advances in autologous CAR T-cell therapies utilize a patient’s own immune T cells, but “”off-the-shelf”” allogeneic CAR T cells have many potential advantages over autologous approaches, including immediate availability of cryopreserved batches, potential standardization of the cell product, time for multiple cell modifications, redosing, and reduced cost. I am working to establish a culture system to produce large numbers of allogeneic genetically modified CAR T cells at low cost, with the goal of improving safety, limiting the potential for graft-versus-host disease, and improving persistence in recipients.
